BAT Smoke-Free Sales Accelerate, Vapes and Pouches Drive Growth
BAT reported accelerating growth in its smoke-free product segment, led by vapes and oral nicotine pouches, signaling a successful pivot away from declining combustible cigarette volumes. This reduces regulatory risk and supports higher margins, making the stock more attractive. The update prompted investors to re-rate the stock, narrowing its discount to competitors.
- ▲ Smoke-free product sales growth beat expectations, driven by strong vape and pouch demand
- ▲ Management affirmed upbeat guidance, citing innovation and brand momentum in next-generation products
- ▼ Increased regulatory scrutiny on vaping and nicotine pouches could tighten marketing and availability
- ▼ Intensifying competition from Philip Morris International and JUUL could dent market share gains
▼ Show FAQ (3) ▲ Hide FAQ
How did BAT's smoke-free pivot impact its stock?
The stock rallied as investors welcomed faster-than-expected growth in the smoke-free portfolio, which reduces reliance on declining cigarette sales and improves long-term profitability prospects.
What are the key products driving BAT's growth?
Vapes, such as Vuse, and oral nicotine pouches, like Velo, are the main drivers, gaining market share and contributing an increasing portion of BAT's revenue.
Is BAT a buy after the smoke-free acceleration?
Analysts are more positive as the successful pivot could lead to multiple expansion, but risks remain from regulation and competitive pressures in the rapidly evolving next-gen nicotine market.